CDC Updates Guidance on RSV Immunization for Young Children

Following manufacturers’ plans to release additional doses of nirsevimab, the CDC updated it recommendations for use of the long-acting monoclonal antibody immunization to prevent RSV-associated lower respiratory tract disease in young children. Although a CDC Health Advisory issued in October recommended prioritization of the drug because of limited supply, CDC and ACIP now recommend that healthcare providers administer a single dose of nirsevimab to all infants aged less than 8 months, as well as children aged 8 through 19 months at increased risk of RSV. Neither Pfizer Abrysvo nor GSK Arexvy RSV vaccines are recommended for use in young children. Read the updated CDC recommendations.